Guía de Práctica Clínica sobre Trastorno Bipolar - GuíaSalud

632. Agencia Española del Medicamento. Nota informativa. Uso de lamotrigina durante el
embarazo: riesgo de fisuras orales. 2006.
633. Holmes LB, Wyszynski DF y Baldwin EJ. Increased risks for nonsyndromic cleft palate
among infants exposed to lamotrigine during pregnancy. Birth Defects Research Part A.
Clinical and Molecular Teratology, 2006; 76: 318.
634. GlaxoSmithKline. The lamotrigine pregnancy registry wilmington. 2010 [cited;
Available from: http://pregnancyregistry.gsk.com/lamotrigine.html.
635. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G y Einarson TR.
Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of
cohort and case-control studies. Bmj, 1998; 317 (7162): 839-843.
636. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT y Olsen J. A population-based casecontrol
teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and
clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol, 2002; 101
(2): 147-154.
637. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation.
Reprod Toxicol, 1994; 8 (6): 461-475.
638. Medrano J, Zardoya M y Pacheco L. Uso de psicofármacos en el embarazo y la lactancia.
EUROMEDICE.: Ediciones Médicas; 2009.
639. Pacheco L y Medrano J. Guía para el uso autorizado de psicofármacos en España
Barcelona: Glosa; 2005.
640. Raphael D, Ross J y Brizedine L. Treating anxiety during pregnancy. Just how to safe are
SSRIs? Current psychiatry reports, 2008; 7: 39-52.
641. Briggs GG, Freeman RK y Yaffe S. Drugs in Pregnancy and Lactation: A Reference
Guide to Fetal and Neonatal Risk. Philadelphia PA, London: Lippincott Williams &
Wilkins.; 2002.
642. Rumeau-Rouquette C, Breart G, Deniel M, Hennequin JF y du Mazaubrun C. [The
concept of risk in perinatology. Results of epidemiologic surveys (author's transl)]. Rev
Epidemiol Sante Publique, 1976; 24 (3-4): 253-276.
643. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW y Shapiro S. Antenatal
exposure to the phenothiazines in relation to congenital malformations, perinatal
mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol, 1977;
128 (5): 486-488.
644. Einarson A y Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J
Psychiatr Pract, 2009; 15 (3): 183-192.
645. Kirchheiner J, Berghofer A y Bolk-Weischedel D. Healthy outcome under olanzapine
treatment in a pregnant woman. Pharmacopsychiatry, 2000; 33 (2): 78-80.
646. Ericson A, Kallen B y Wiholm B. Delivery outcome after the use of antidepressants in
early pregnancy. Eur J Clin Pharmacol, 1999; 55 (7): 503-508.
647. Hemels ME, Einarson A, Koren G, Lanctot KL y Einarson TR. Antidepressant use during
pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother,
2005; 39 (5): 803-809.
648. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D y Altshuler L. Birth outcomes after
prenatal exposure to antidepressant medication. Am J Obstet Gynecol, 2003; 188 (3):
812-815.
649. Food and Drug Administration. Public Health Advisory: Paroxetine. 20058.
650. Gentile S y Bellantuono C. Selective serotonin reuptake inhibitor exposure during early
pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin
Psychiatry, 2009; 70 (3): 414-422.
651. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium
toxicity profile: a systematic review and meta-analysis. Lancet. 2012 Feb 25; 379(9817):
721-8.
436 SANIDAD